Start-up investor Eve Investments has an interesting medical portfolio in Australia: in May it was cannabis honey, yesterday their diabetes shake went to China.

One of Eve’s (ASX:EVE) investment vehicles, Omni Innovation, yesterday struck a deal to sell its pre-meal shakes for Type 2 and pre-Type 2 diabetes in China via ASX-listed distributor Eagle Health.

It may sound like a Belle Gibson-esque claim – a medical milkshake that can control diabetes. But ongoing studies by teams from Adelaide University and Curtin University suggest the vanilla and chocolate flavoured concoctions work.

The agreement is for a $1.5 million licensing fee, a $1 million payment after the agreement is signed, and a $500,000 payment once the shake is registered as medicinal food with the China Food and Drug Administration.

Eve’s other investment, a $1.49 million deal to buy 50 per cent of an organic essentials oils company from Jenbrook Ltd in NSW, includes a play on cannabis honey.

Director Bill Fry told Stockhead the appeal wasn’t the cannabis element — which is still being tested — but the medicinal benefits of the honey and the tea tree oil.

Eve completed a capital raising in early May for $1.1 million — but had no sales receipts in the quarter. It spent $916,000 in the period, leaving $260,000 in the bank at the end of June. Eve expects to spend $189,000 in the current quarter.

Eve’s shares have traded between 0.3c and 1.2c over the past year. Shares now trade at about 0.5c, valuing the company at $7.4 million.

Eagle Health Holdings, which makes protein powder and vitamins, listed in June and wants to capitalise on Australia’s clean image to distribute health products from this country in China.

Featured Companies

You might be interested in